A review of the cardiovascular and breast actions of drospirenone in preclinical studies

References

• Consensus conference on hormone replacement therapy, October 2003. Final consensus statement. Royal College of Physicians of Edinburgh. Accessed 24 June, 2009
   Google Scholar
• Nelson HD. Menopause. Lancet 2008;371:760–770
   PubMed Web of Science ®Google Scholar
• Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117–125
   PubMed Web of Science ®Google Scholar
• Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
   PubMedGoogle Scholar
• Sasser AC, Rousculp MD, Birnbaum HG, et al Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Women's Health Issues 2005;15:97–108
   PubMed Web of Science ®Google Scholar
• Van der Schouw YT, van der Graaf, Steyerberg EW, et al Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714–718
   PubMed Web of Science ®Google Scholar
• Archer DF. Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. Semin Reprod Med 2005;23:188–795
   PubMed Web of Science ®Google Scholar
• National Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related Symptoms. Ann Intern Med 2005;142:1003–1013
   PubMedGoogle Scholar
• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;October 18: CD002978
   Google Scholar
• Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. Climacteric 2007;10:88–96
   PubMed Web of Science ®Google Scholar
• Grady D, Ruben SB, Petitti DB, et al Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–1037
   PubMed Web of Science ®Google Scholar
• Corson SL, Richart RM, Caubel P, et al Effect of unique constant estrogen, pulsed-progestin hormone replacement therapy containing 17β-estradiol and norgestimate on endometrial histology. Int J Fertil Womens Med 1999;44:279–285
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801–1811
   PubMed Web of Science ®Google Scholar
• Fu XD, Simoncini T. Non-genomic sex steroid actions in the vascular system. Semin Reprod Med 2007;25:178–186
   PubMed Web of Science ®Google Scholar
• Simoncini T, Fu X-D, Caruso A, et al Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007;22:2325–2334
   PubMed Web of Science ®Google Scholar
• Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:1680–1687
   PubMed Web of Science ®Google Scholar
• Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757–1761
   PubMed Web of Science ®Google Scholar
• Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217–221
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, et al Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357–365
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35–44
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–1477
   PubMed Web of Science ®Google Scholar
• Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease – why renew the focus on the early years of menopause? Am J Epidemiol 2007;166:511–517
   PubMed Web of Science ®Google Scholar
• Women's Health Initiative Steering Committee. Effects of equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701–1712
   PubMed Web of Science ®Google Scholar
• Chen WY, Manson JE, Hankinson SE, et al Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027–1032
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–454
   PubMed Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–1280
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–111
   PubMed Web of Science ®Google Scholar
• Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915–920
   PubMed Web of Science ®Google Scholar
• Winneker RC, Parsons JA. Glucocorticoid-like actions of medroxyprogesterone acetate upon mTTW15 rat mammosomatotrophic pituitary tumours. Endocrinology 1981;109:99–105
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865–883
   PubMed Web of Science ®Google Scholar
• Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891–905
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005;8(Suppl 3):4–12
   PubMed Web of Science ®Google Scholar
• Oelkers W. Drospirenone, a progesterone with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004;217:255–261
   PubMed Web of Science ®Google Scholar
• Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;46(Suppl 1):S31–s37
   PubMedGoogle Scholar
• Muhn P, Fuhrmann U, Fritzemeier KH, et al Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311–335
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater EP, et al The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243–251
   PubMed Web of Science ®Google Scholar
• Pollow K, Juchem M, Elger W, et al Dihydrospirorenone (ZK30595): a novel synthetic progesterone – characterization of binding to different receptor proteins. Contraception 1992;46:561–574
   PubMed Web of Science ®Google Scholar
• Oelkers WKH. Effects of estrogens and progestogens on the renin–angiotensin system and blood pressure. Steroids 1996;61:166–171
   PubMed Web of Science ®Google Scholar
• Green S, Walter P, Greene G, et al Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 1986;24:77–83
   PubMedGoogle Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, et al Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925–5930
   PubMed Web of Science ®Google Scholar
• Arias-Loza PA, Hu K, Schafer A, et al Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17β-estradiol in aldosterone salt-treated rats. Hypertension 2006;48:994–1001
   PubMed Web of Science ®Google Scholar
• Booth EA, Lucchesi BR. Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2007;293:H1408–H1415
   PubMed Web of Science ®Google Scholar
• Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause 2006;13:80–86
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, et al Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745–5756
   PubMed Web of Science ®Google Scholar
• Seeger H, Wallwiener D, Mueck AO. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 2009;12:80–87
   PubMed Web of Science ®Google Scholar
• Oishi A, Ohmichi M, Takahashi K, et al Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004;324:193–198
   PubMed Web of Science ®Google Scholar
• Clarkson TB. Progestogens and cardiovascular disease. A critical review. J Reprod Med 1999;44(Suppl 2):180–184
   PubMed Web of Science ®Google Scholar
• Kublickiene K, Fu XD, Svedas E, Landgren BM, Genazzani AR, Simoncini T. Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab 2008;93:1874–1883
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Mannella P, Simoncini T. Drospirenone and its antialdosterone properties. Climacteric 2007;10(Suppl 1):11–18
   PubMed Web of Science ®Google Scholar
• Archer DF, Thorneycroft IH, Foegh M, et al Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716–727
   PubMed Web of Science ®Google Scholar
• White WB, Pitt B, Preston RA, et al Antihypertensive effects of drospirenone with 17-beta-estradiol, a novel hormone treatment in post-menopausal women with Stage 1 hypertension. Circulation 2005;112:1979–1984
   PubMed Web of Science ®Google Scholar
• White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006;48:246–253
   PubMed Web of Science ®Google Scholar
• Preston RA, Alonso A, Panzitta D, et al Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002;15:816–822
   PubMed Web of Science ®Google Scholar
• Preston RA, White WB, Pitt B, et al Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797–804
   PubMed Web of Science ®Google Scholar
• Preston RA, Norris PM, Alonso AB, Ni P, Hanes V, Karara AH. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007;14:408–414
   PubMed Web of Science ®Google Scholar
• Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol Endocrinol 2007;23:692–699
   PubMed Web of Science ®Google Scholar
• Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005;8(Suppl 3):19–27
   PubMedGoogle Scholar
• Said TK, Conneely O, Medina D, O'Malley BW, Lydon JP. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 1997;138:3933–3939
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559–4565
   PubMed Web of Science ®Google Scholar
• Masters JR, Drife JO, Scarisbrick JJ. Cyclic variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst 1977;58:1263–1265
   PubMed Web of Science ®Google Scholar
• Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK. Essential function of wnt-4 in mammary gland development downstream of progesterone signalling. Genes Dev 2000;14:650–654
   PubMed Web of Science ®Google Scholar
• Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 2004;9:3–13
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. PNAS 2003;100:9744–9749
   PubMed Web of Science ®Google Scholar
• Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987–4991
   PubMed Web of Science ®Google Scholar
• Otto C, Fuchs I, Altmann H, et al Drospirenone, but not medroxyprogesterone acetate, shows a favourable dissociation of uterine versus mammary gland effects. Endocrinology 2008;149:3952–3959
   PubMed Web of Science ®Google Scholar
• Bray JD, Jelinsky S, Ghatge R, et al Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 2005;97:328–341
   PubMed Web of Science ®Google Scholar
• Fu XD, Giretti MS, Baldacci C, et al Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE 2008;3:e2790
   PubMed Web of Science ®Google Scholar
• Fu XD, Giretti MS, Goglia L, et al Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer 2008;8:166
   PubMed Web of Science ®Google Scholar
• Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells. Menopause 2005;12:468–474
   PubMed Web of Science ®Google Scholar
• Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod Biol 2006;129:77–83
   PubMed Web of Science ®Google Scholar